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Abstract:

Objectives: Appropriate chemotherapy and radiation near end of life is a moving target; challenged by increasing costs, evolving
therapies, new reimbursement models and quality metrics. We review treatment trends and variables impacting the initiation of
chemotherapy (CHT) and radiotherapy (XRT) in the final 60, 30 and 14 days of life in metastatic non-small cell lung cancer (NSCLC).
Methods: The Florida Cancer Data System was studied to complete a retrospective cohort analysis of 48,858 individuals with Stage IV
(M1) NSCLC from 1995–2010. We evaluated the initiation of CHT and XRT after diagnosis and associations with patient demographics,
insurance and socioeconomic status (SES).
Results: The use of CHT increased from 35% to 49%, while XRT decreased from 52% to 37% between 1995 and 2010. Initial courses
of CHT occurred 8.1%, 5.0%, and 3.6% in the final 60, 30, and 14 days of life, and XRT 13.8%, 7.7%, and 5.2% of the time, respectively.
Younger, married, and male patients were more likely to receive treatment. Low SES (OR 0.685, 95% CI 0.633–0.741) and uninsured
individuals (OR 0.678, 95% CI 0.572–0.804) were less likely to receive CHT. SES and insurance did not impact XRT.
Conclusions: The initiation of late CHT and XRT treatments decreased from 1995–2010. It persisted above 3% in the last 14 days of
life. Clinicians may struggle to taper treatment before death, especially in patients with limited survival. It is important to recognize the
complexities of death and dying and the potential influences of palliative care in affecting treatment decisions.
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1. Introduction
Advancements in cancer therapies and the integration of
palliative care have contributed greatly to improvements
in quality of life and survival for individuals with
metastatic non-small cell lung cancer (NSCLC).
However, as healthcare costs escalate and providers
shift toward value-based care, the debate remains about
the appropriate utilization of medical resources near the

end of life. This issue is compounded by the increasing
burden of cancer in the population. Given the current
trends, U.S. costs of cancer care are expected to reach
$174 billion by 2020, a 39% increase since 2010.(1)
The majority of cancer costs are incurred during the
final months of life. During this time, the appropriate
delivery of chemotherapy and radiation remains a
challenge due to difficulties with prognostication and
a sparsity of evidence-based guidelines.(2–5) Prior
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studies have shown that up to 25% of cancer patients
getting chemotherapy and/or radiation near the end
of life are treated without clear benefits.(6–8) While, the
intention of thoracic radiation near the end of life is
presumably palliative, even the tolerance of a short
course of palliative thoracic radiation for moderate
symptoms (cough, hemoptysis, thoracic pain, dyspnea,
hoarseness or dysphagia) may be poor and nonbeneficial, compared to best supportive care.(9) In many
cases, symptoms may be palliated by means other than
chemotherapy or radiation. Nonetheless, it is unclear to
call this over utilization in the setting of diagnoses when
new patients are functionally limited, but motivated to try
treatment regardless.
In the midst of our understanding, contemporary
discussions amongst oncologists and a growing body
of evidence are establishing improved outcomes and
reduced costs with the integration of palliative care
for advanced cancer patients. Guidelines put forth by
the Choosing Wisely Campaign, American Society of
Clinical Oncology (ASCO) and the National Quality
Forum (NQF) recommend early integration of palliative
care to potentially achieve better quality of life, patient
satisfaction, caregiver burden and even survival.(10)
New palliative oncology specialist services may change
utilization patterns of chemotherapy and radiation
near the end of life, offering more timely treatment or
reducing the number of over-aggressive treatments
close to death.(11) This may help reduce “aggressive
treatments”, or those which are costly and/or do little to
improve survival or quality of life before death.
In the next several years, states and regions across
the globe will be called to manage larger burdens of
cancer, especially among the elderly. In light of care
quality and cost, it is important to consider the treatment
rates and variables impacting the end of life management.
In particular, treatments initiated in the last 14 days of life
generally adds little value – or can be detrimental – to
patient care. To understand the trend of modern treatment
patterns near the end of life, we study Florida, which has
the largest portion of elderly patients and second-highest
total Medicare enrollees in the country.(12)
As cancer care develops, the initiation of
chemotherapy and radiotherapy should decrease in the
last days of life for which the marginal benefit becomes
questionable. Barring prognostic limitations, we believe
that initial courses of treatment should taper near the
end of life (e.g., less people starting treatment 0–14
days from death than 15–30 days from death). This
study reviews the longitudinal trends of cancer treatment
surrounding the final weeks of life. We discern relevant
socioeconomic factors that impact the utilization of
resources near the end of life. Given the shift to value30

based care, we provide valuable awareness towards the
timing of clinical decisions near the end of life in terminal
cancer patients.

2. Methods
We performed a retrospective cohort analysis of
individuals diagnosed with Stage IV (M1) NSCLC
between 1995 and 2010 using the Florida Cancer Data
System (FCDS). All individuals resided in the state
of Florida and were over the age of 18 years at the
time. This data was obtained from the State of Florida
Department of Health, which contracts the FCDS housed
at the University of Miami. The FCDS is a populationbased cancer registry with gold-level certification from
the North American Association of Central Cancer
Registries since 1996.(13) With few exceptions, all cancer
cases diagnosed or treated in Florida (since 1981) are
reported to the FCDS, regardless of insurance and
medical provider. The FCDS collects information on
diagnosis, stage of disease, patient demographics,
residence and methods of treatment.(14)
The FCDS records the first treatment courses of
chemotherapy and radiation for each patient after
Stage IV diagnosis. We studied all initial treatments
of chemotherapy and radiotherapy and included a
time-series analysis for every two-year period. We
categorized treatments as occurring in the last 14, 30,
60, or greater than 60 days of life.
Our main analysis does not capture treatments
after the first course. Therefore, those with early initial
treatments may have had undocumented later courses
of treatment in the FCDS. However, patients with a
small survival window are more likely to have their first
course of treatment be their last. To study differences
in this population and better understand near-end-of-life
utilization rates, we performed an extra subset analysis
that included only those who died 60 days or less after
diagnosis.
Statistical analysis was performed using R version
3.0.2. Univariate statistics were run to quantify patient
characteristics. Continuous variables were compared
using the Wilcoxon rank sum test, while categorical
variables were compared using Pearson’s Chi-Square
test. All univariate tests were two-tailed, with a p-value of
≤ 0.05 considered significant. Logistic regression models
were run to determine the association between insurance
types, socioeconomic status (SES), marital status, sex,
age at diagnosis and the receipt of chemotherapy and
radiation. Those from residences in which < 5%, 5–20%,
or 20–100% of neighborhood households fell below the
federal poverty level were considered high, middle, or
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low SES, respectively. Survival times were computed
using Kaplan-Meier estimate.

Utilization of CHT and XRT
For Stage IV NSCLC
60

3. Results

50

3.1. Patient Characteristics

3.2.

Chemotherapy and Radiotherapy
Treatment Patterns

Time trends of percent utilization are shown in Figure 1.
A total of 21,573 patients received chemotherapy and
21,633 patients received radiotherapy. From 1995 to
2010, chemotherapy use increased from 35% to 49%
of cases, while radiotherapy use decreased from 52%
to 37%. Recommended treatment was refused by 3%
of chemotherapy patients (N = 703) and less than 1% of
radiotherapy patients (N = 137).
When treated, 11,983 patients received both
chemotherapy and radiotherapy before death. Of these,
27% received concurrent treatment, 40% received
chemotherapy first and 33% received radiation first.
Besides these, 9,590 patients received chemotherapy
without radiotherapy, and 9,650 patients received
radiotherapy without chemotherapy. The median time
from diagnosis to the start of chemotherapy was 20
days, and from diagnosis to the start of radiation was 26
days. The median time from the start of chemotherapy to
death was 192 days, and from the start of radiotherapy
to death was 130 days. 17,635 patients did not receive
chemotherapy or radiotherapy.
Treatment near the end of life was divided into
intervals of 0–14 days, 15–30 days, 31–60 days, and
> 60 days from death in Table 2. From 1995 to 2010,
chemotherapy patients (N = 21,573) grew less likely
to start their first chemotherapy treatment in the last
14, 30 and 60 days of life. Chemotherapy treatment
in the last 0–14 days decreased from 4.0% to 3.2%,
15–30 days decreased from 5.2% to 3.9%, and 31–60

% Utilization

We evaluated 48,858 patients who met the inclusion
criteria for this study. Patient characteristics are shown
in Table 1. The 25th, 50th and 75th quartiles for age at
diagnosis were 60, 69 and 76 years, respectively. The
quartiles for survival time were 2.4 months, 4.8 months
and 12 months. 56% of patients were married, 17%
widowed, 13% single, 11% divorced and 3% unknown.
Patients were 14% high SES, 68% middle SES and 17%
low SES. The total population with insurance was 81%.
Of those insured, Medicare comprised 66%, Private
25%, Medicaid 6% and Military 2%.

40
30

XRT
CHT

20
10
0

Figure 1: Utilization of CHT and XRT. The percentage of patients that
initiated chemotherapy and radiotherapy any time after diagnosis of Stage
IV NSCLC is shown. Trends are shown in two-year time frames between
1995 and 2010.

days decreased from 9.2% to 7.7%. During this time,
radiotherapy patients (N = 21,633) also grew less
likely to start their first radiation treatment in the last
14, 30, and 60 days of life. Radiation treatment in the
last 0–14 days decreased from 5.8% to 4.0%, 15–30
days decreased from 7.3% to 7.0%, and 31–60 days
decreased from 14% to 12.6%.

3.3.

Subset Analysis in 60-Day Limited
Survival

Within our study, 12,910 (26%) patients met the criteria for
our subset analysis, which included only those patients
who survived less than 60 days after diagnosis. In total,
3,660 (28%) and 1,991 (15%) received radiotherapy
and chemotherapy, respectively. The initiation of
chemotherapy and radiation treatments for these
patients is shown in Figure 2. Usage of radiotherapy
decreased from 35% in 1995 to 21% in 2010. On the
other hand, the use of chemotherapy remained even at
15%. Overall, initiation in the last 60, 30 and 14 days of
life was 28%, 18% and 8% for radiotherapy and 15%,
10% and 5% for chemotherapy, respectively.

3.4.

Socioeconomic Factors Impacting
Treatment

Factors associated with the treatment are highlighted
in Table 3. Individuals receiving chemotherapy were
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Table 1: Patient Characteristics.

Characteristic

Diagnosed Patients

CHT Treatment

XRT Treatment

60 69 76

--

--

Survival after Diagnosis (months)

2.4 4.8 12.0

--

--

Diagnosis to Treatment (months)

--

0.4 0.9 1.5

0.3 0.7 1.4

Treatment to Death (months)

--

2.8 6.4 13.2

1.8 4.3 10.0

Male | Female

58% | 42%

58% | 42%

60% | 40%

White | Non-White

83% | 17%
% CHT Treated

% XRT Treated

N = 48,858

44%

44%

CHT and XRT

11,983

100%

100%

CHT and not XRT

9,590

100%

0%

XRT and not CHT

9,650

0%

100%

Neither

17,635

0%

0%

Age at Diagnosis (years) ± quartiles

Patients Diagnosed 1995 to 2010
Treatment Before Death

Marital Status
27,592

49%

46%

Widowed

Married

8,180

32%

36%

Single

6,152

42%

45%

Divorced

5,586

44%

47%

Unknown

1,348

38%

46%

Low

6,901

50%

45%

Middle

33,430

44%

44%

High

8,527

40%

46%

SES

Insurance Status
Insured

39,575

44%

43%

Medicare

26,302

39%

39%

Private

9,947

55%

48%

Medicaid

2,476

48%

52%

Military

895

45%

58%

Not insured

2,443

42%

48%

Unknown

6,840

46%

51%

Table 2: Timing of treatment initiation in Stage IV NSCLC Patients from 1995 - 2010.
Years:

95-96

97-98

99-00

01-02

03-04

05-06

07-08

09-10

Total

Patients who initiated first course of radiotherapy
> 60 days from death

72.9%

73.9%

72.3%

72.6%

73.4%

72.9%

72.3%

76.3%

73.3%

31-60 days from death

14.0%

12.9%

15.1%

14.3%

13.2%

14.0%

14.7%

12.6%

13.8%

15-30 days from death

7.3%

8.3%

7.4%

7.8%

7.9%

7.5%

7.9%

7.0%

7.7%

0-14 days from death

5.8%

5.0%

5.1%

5.3%

5.6%

5.6%

5.1%

4.0%

5.2%

Patients who initiated first course of chemotherapy
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> 60 days from death

81.6%

82.7%

82.7%

82.6%

83.4%

84.0%

83.7%

85.2%

83.3%

31- 60 days from death

9.2%

8.3%

9.0%

9.5%

8.7%

8.5%

8.8%

7.7%

8.1%

15-30 days from death

5.2%

5.3%

5.1%

4.5%

4.1%

4.8%

4.4%

3.9%

5.0%

0-14 days from death

4.0%

3.8%

3.2%

3.4%

3.7%

2.7%

3.1%

3.2%

3.6%
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Initiation of Treatments for Stage IV NSCLC
in 60-Day Limited Survival
40

35

% Initiation

30

XRT within 60 days of death

25

XRT within 30 days of death
XRT within 14 days of death

20

CHT within 60 days of death
CHT within 30 days of death

15

CHT within 14 days of death

10

5

0

1995-96

1997-98

1999-00

2001-02

2003-04

2005-06

2007-08

2009-10

Figure 2: Initiation of Treatments for Stage IV NSCLC in 60-Day Limited Survival. Only patients with a 60-day or less survival from date of diagnosis to
date of death are included. The percentage of patients that initiated radiotherapy (red lines) and chemotherapy (blue lines) within each time frame after
diagnosis of Stage IV NSCLC is shown: within 60 days of death, within 30 days of death, and within 14 days of death. Trends are shown in two-year time
frames between 1995 and 2010.

Table 3: Factors Impacting Utilization.
Radiotherapy Received
Characteristic

OR

95% CI

P (Wald statistics)

Age 70: 65

0.897

(0.887, 0.908)

< 0.0001

Low SES: Middle SES

1.015

(0.959, 1.074)

Low SES: High SES

1.073

(0.992, 1.160)

Not Married: Married

0.938

(0.896, 0.982)

0.006

Not Insured: Insured

0.852

(0.721, 1.007)

< 0.0001

Female: Male

0.863

(0.826, 0.903)

< 0.0001

CHT Received-Yes: No

0.593

(0.567, 0.619)

< 0.0001

0.173

Chemotherapy Received
Characteristic

OR

95% CI

P (Wald Statistics)

Age 70: 65

0.824

(0.814, 0.834)

< 0.0001

Low SES: Middle SES

0.830

(0.783, 0.880)

Low SES: High SES

0.681

(0.629, 0.738)

Not Married: Married

0.702

(0.671, 0.736)

< 0.0001

Not Insured: Insured

0.678

(0.572, 0.804)

< 0.0001

Female: Male

1.077

(1.029, 1.127)

0.001

XRT Received-Yes: No

0.593

(0.568, 0.620)

< 0.0001

< 0.0001
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less likely to receive radiotherapy and vice versa. Older
individuals were less likely to receive radiotherapy and
chemotherapy. Individuals that were classified as not
married (single, divorced, widowed) were less likely to
receive radiotherapy (OR 0.938; 95% CI 0.896, 0.982)
and chemotherapy (OR 0.702; 95% CI 0.671, 0.736).
Widowed patients accounted for the greatest difference
in receiving chemotherapy (32% vs. 49% married) and
radiotherapy (36% vs. 46% married).
SES did not impact the odds of receiving
radiotherapy, while low SES patients (measured as
individuals living in high poverty areas) were less likely
to receive CHT (OR, 0.685, 95% CI, 0.633–0.741).
Insurance status did not impact the odds of receiving
radiotherapy (OR 0.852; 95% CI 0.721, 1.007) but it did
affect chemotherapy (OR 0.678; 95% CI 0.572, 0.804).
Between Medicare and privately insured patients, there
was no difference in the odds of receiving radiotherapy
(OR 1.014, 95% CI 0.954, 1.079) or chemotherapy (OR
0.957; 95% CI 0.898, 1.019). However, military patients
were significantly more likely to receive radiotherapy
(OR 1.434, 95% CI 1.220, 1.686) and less likely to
receive chemotherapy (OR 0.698, 95% CI 0.594,
0.821) compared to privately insured patients. Medicaid
patients were also more likely to receive radiotherapy
(OR 1.191, 95% CI 1.070, 1.326) and less likely to
receive chemotherapy (OR 0.758, 95% CI 0.679, 0.845)
than privately insured patients. Females were less
likely to receive radiotherapy (OR 0.863; 95% CI 0.826,
0.903), and slightly more likely to receive chemotherapy
(OR 1.077; 95% CI 1.029, 1.127).

4. Discussion
Clinical management near the end of life is an ongoing
challenge. Limited studies exist regarding treatment
utilization, which tend to be single-institution or singlepayer based and may be biased by individual physician
or payer preferences. Our study reviews the Florida
state-wide registry, which includes a broad patient,
provider and payer mix. In doing so, we capture the
modern large-scale trends surrounding advanced
cancer care. Furthermore, we believe that identifying
the initiation of treatments provides valuable new
awareness towards the timing of clinical decisions near
the end of life in terminal cancer patients.
Among our 48,585-patient cohort from 1995 to 2010,
the utilization of chemotherapy increased from 35% to
49%. The increased use of chemotherapy was likely
due to improvements in treatment options, including
targeted agents and tolerability. Although chemotherapy
was used more often, the proportion of individuals
34

initiating chemotherapy near the end of life decreased.
By 2010, chemotherapy treatments were initiated 31–
60 days from death 7.7% of the time, 15–30 days from
death 3.9% of the time, and 0–14 days from death 3.2%
of the time.
On the other hand, radiotherapy utilization
decreased from 52% to 37% of cases. The proportion
of individuals initiating radiotherapy near the end of life
also decreased. By 2010, radiotherapy treatments were
initiated 31–60 days from death 12.6% of the time, 15–
30 days from death 7.0% of the time, and 0–14 days
from death 4.0% of the time. These results also show
that initial radiotherapy treatments occurred closer to
death than chemotherapy treatments.
Our figures are similar to a large Medicare-based
study in 2004, which found that 9% of cancer decedents
received chemotherapy in their last month of life.(15) Our
findings are also comparable to other near-end-of-life
radiation studies,(16–18) whose rates of radiation utilization
ranged from 7.6 to 10.3% in the last 30 days of life and
4.2 to 10% in the last 14 days of life.
We also conducted a subset analysis, which
considered 12,910 patients that had a relatively small
window of survival (60 days or less). This way, each
patient’s first course of treatment was likely to have been
their last. From 1995 to 2010, radiotherapy utilization in
60-day limited survival decreased from 35% to 21% of
cases. The average utilization rate was 18% in the last
30 days and 8% in the last 14 days of life. On the other
hand, chemotherapy utilization in 60-day limited survival
remained at 15% from 1995 to 2010. The chemotherapy
utilization rate was 10% in the last 30 days and 5% in the
last 14 days of life. As the marginal benefit of treatment
decreases, the use of CHT or XRT should become
tapered in the last 30 and 14 days of life. However,
an equal number of chemotherapy patients initiated
treatment in the last 14 days of life compared to the last
15–30 days of life. The appropriate tapering of treatment
may be difficult in patients with 60-day limited survival,
given these patients likely presented later in their illness
or struggled with more rampant disease compared to
our primary cohort.
In total, 3.6% and 5.2% of chemotherapy and
radiation courses are initiated in the last 14 days of
life, when patients are unlikely to experience clinical
benefit from treatment. These treatments are costly
to patients and payers, have risks for side effects
and complications, and can be stressful for patients,
providers and caregivers. This point underlies our
discussion regarding appropriate utilization of resources
in patients with imminent death, those most vulnerable
to quick treatment decisions, and those who suffer from
inaccurate prognostication.
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Our review illustrates the modern paradigm that
palliative treatment is accepted by nearly all patients
to whom it is offered. In our analysis, 31,223 (63.9%)
patients received some form of chemotherapy or
radiotherapy after diagnosis, whereas recommended
treatment was refused by only a very small number of
patients – just 703 chemotherapy and 137 radiotherapy
patients. Previous studies have demonstrated that
64–81% of patients do not understand that palliative
treatment is not curative for their stage IV cancer.
(19,20)
Without clear communication, physicians are in a
dangerous position to prescribe treatments near the end
of life whose benefits may be unclear to patients.
We explored individual factors that impacted the odds
of receiving chemotherapy and radiotherapy. Uninsured
individuals and those living in impoverished areas were
less likely to receive chemotherapy. On the other hand,
the odds of receiving radiotherapy were independent
of SES and insurance status. Possible explanations
include the medical and logistical differences between
chemotherapy and radiation. Whereas higher
performance status is required for chemotherapy and
often includes frequent follow-up and laboratory studies,
palliative radiotherapy is typically a shorter treatment
course (for instance, one fraction for the palliation of
bone metastases), requires less visits and remains an
option even for patients with poor performance status.
Data on the effects of SES and access to palliative care
are limited but emerging.(21) Notably, performance status
is not a variable recorded in the FCDS, and this limitation
alone may reduce prognostic awareness and influence
over utilization by oncology providers for either treatment
modality. Married individuals were more likely to receive
treatments, which could reflect the social support
often required for treatment. On average, caregivers
provide 8 hours of daily assistance including personal
care, symptoms management, transportation and care
coordination for individuals with advanced cancer.(22)
Earlier integration of palliative care may improve quality
of life, depression and stress burden for caregivers.(23)
Despite improvement efforts, overtreatment near
the end of life is an ongoing debate complicated by
multiple factors including the heterogeneity of cancer
and inadequacies with prognostication. Several studies
have demonstrated that physicians are overly optimistic
by a time factor of two to five-fold.(2–5) Patients and
physicians often share intrinsic biases; overestimating
the benefits of treatment and preserving the inherent
desire to do “everything possible”.(24–26) Moreover,
patients are willing to suffer large treatment toxicities for
marginal gains.(27)
The evolution of metastatic disease can be
tumultuous, whereas the current prognostication tools,

such as performance status, are subject to bias and
limitations. For instance, there are data in geriatric
oncology where patients have a good performance
status but limited ability to tolerate the physiologic
burden of tumor-directed therapy and decline quickly
after initiating treatment.(28) Calls for improvement have
been made.(29,30) In addition to the prognostic challenges,
there are several institutional barriers that limit the
integration of hospice and palliative care. These include
insurance mandates, cost constraints, limited resources,
as well as physician buy-in for palliative services.(31–33)
In light of the aforementioned realities, “overutilization” of chemotherapy and radiation are
foreseeable issues. Cautious tones should be used
when defining appropriate and inappropriate care,
particularly when shared decision making and informed
consent have occurred. Quality metrics put forth by
the National Quality Forum and Choosing Wisely
Campaign® recommend palliative care for any individual
with a terminal illness who has physical, psychological,
social or spiritual distress.(34) These guidelines also state
that chemotherapy should not be given within 14 days of
death, while there are no guidelines on the optimal timing
of palliative radiation. In this study, 2–8% of individuals
started radiation and 2–5% started chemotherapy within
14 days of death. Given the complex bio-psycho-socialspiritual dimensions of death and dying, it may not be
reasonable to expect these numbers to drop significantly
further. Yet, as accountability care organizations expand
and insurance reimbursement structures rely more
on quality metrics, we are called to address our own
standards for cancer care.(35–37)
Standardized management near the end of life is
challenged further by rapidly evolving therapies. The first
immunotherapy agents (Nivolumab and Pembrolizumab)
were FDA-approved for NSCLC in 2015 and have had
dramatic implications in survival outcomes. This study
observes treatment patterns in the pre-immunotherapy
era from 1995–2010. Future directions should evaluate
and compare near-end-of-life radiotherapy utilization
pre- and post- pervasive adoption of immunotherapy for
patients with advanced NSCLC, and its implications for
the discussion with the patient.
It has been shown that end of life discussions
significantly
reduce
over-aggressive
medical
interventions near the time of death and even improve
survival. Also, it has been well documented that
additional education in these areas is needed for our
trainees.(15,38,39) Perhaps, there should be less focus
on utilization percentages and more focus on patient
centered discussions that influence decision-making. If a
patient and physician carefully discuss prognosis, goals
of care and treatment options, and the patient decides
35
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to proceed with therapy, is this a misappropriation of
medical resources? Rather than try to base quality
of care on the timing of radiotherapy, perhaps the
primary measure should be goals of care discussions
documented with patients. As we examine treatment
utilization patterns as an area for reform, especially for
high-risk individuals, the oncologist’s careful, focused
and thoughtful care should be targeted to all patients
facing terminal illness.

4.1. Study Limitations
Clinicians continue to struggle with accurate
prognostication; therefore, treatment decisions may
be influenced by estimated survivability before death.
There are multiple confounding variables that predict
disease outcomes and these impact recommendations
for or against conventional treatment modalities,
including disease burden and site, comorbidities,
molecular characteristics, and performance status. As
mentioned in our discussion, the FCDS does not record
performance status, and this study does not capture
those intricacies.
The use of radiation may be underreported in large,
population based cohorts.(40) Our primary analysis,
which only captures the initial chemotherapy and
radiotherapy treatments, does not fully reveal the
number of treatments that occurred late near end of
life. This is reflected in the higher utilization rates seen
near the end of life in the 60-day limited survival subset.
Lastly, while our study shows the number of patients
that received chemotherapy and radiotherapy (versus
just chemotherapy or just radiotherapy), it does not
show time trends or covariate analysis for the usage of
combination therapy.

5. Conclusion
When examining the Florida state-wide cancer registry,
the initiation of late chemotherapy and radiation
treatments decreased from 1995–2010, but persisted
at above a 3% baseline level in the last 14 days of
life. Clinicians may struggle to taper treatment before
death, especially in patients with limited survival.
Younger, married and male patients were statistically
more likely to receive palliative treatments. Insurance
and SES did not influence the delivery of radiation,
but did impact the use of chemotherapy. More work
remains to be explored regarding disease burden and
prognostic characteristics that affect the susceptibility to
over-aggressive treatments. When defining quality care
metrics, it is important to recognize the complexities of
death and dying and the potential influences of palliative
care in affecting decision-making regarding the delivery
of treatment near the end of life.
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